DEVOTE 3:严重低血糖、心血管结局与死亡率之间的时间关系
DEVOTE 试验的二次分析评估2型糖尿病心血管高危患者中严重低血糖与MACE及全因死亡的关联。严重低血糖后MACE风险差异无统计学意义(HR 1.38,95%CI 0.96,1.96;p=0.080),全因死亡风险显著升高(HR 2.51,95%CI 1.79,3.50;p<0.001),且在低血糖后15至365天各时间点均观察到死亡风险升高。
要点
- 严重低血糖后MACE风险未达统计学显著(HR 1.38,95%CI 0.96,1.96;p=0.080)。
- 严重低血糖后全因死亡风险显著升高(HR 2.51,95%CI 1.79,3.50;p<0.001)。
- 严重低血糖后15、30、60、90、180和365天全因死亡风险均高于同期未发生严重低血糖者。
核心结论
- 分析显示严重低血糖与全因死亡存在关联,经历严重低血糖的患者在低血糖事件后短期内死亡风险尤其更高。
- 这些发现提示严重低血糖与后续死亡率升高相关,但不能回答严重低血糖是不良结局的风险标志还是存在直接因果效应。
研究设计与样本
- DEVOTE为事件驱动、双盲、治疗达标的心血管结局试验,2型糖尿病患者随机接受每日一次(晚餐至睡前)德谷胰岛素或甘精胰岛素U100(100单位/ml)治疗。
- 本分析在汇总试验人群中采用时间至事件分析评估严重低血糖与MACE及全因死亡的关联,严重低血糖作为时依变量,随机治疗作为固定因素。
- 交互项分析表明严重低血糖对MACE和全因死亡风险的影响在两个治疗组相同,故报告汇总人群中严重低血糖与后续MACE及全因死亡的时间关联。
主要发现
- 试验期间发生 vs 未发生严重低血糖者MACE风险差异无统计学意义(HR 1.38,95%CI 0.96,1.96;p=0.080),严重低血糖与MACE之间无时间关系。
- 试验期间发生 vs 未发生严重低血糖者全因死亡风险显著更高(HR 2.51,95%CI 1.79,3.50;p<0.001)。
- 经历严重低血糖后15、30、60、90、180和365天,全因死亡风险均高于同一时间间期内未经历严重低血糖者。
- 对年龄、性别、HbA1c、BMI、糖尿病病程、胰岛素方案、肝损伤、肾脏状态和心血管风险组这些基线特征校正后,严重低血糖与全因死亡的关联依然存在。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) assessed the cardiovascular safety of insulin degludec. The incidence and rates of adjudicated severe hypoglycaemia, and all-cause mortality were also determined. This paper reports a secondary analysis investigating associations of severe hypoglycaemia with cardiovascular outcomes and mortality. METHODS: In DEVOTE, patients with type 2 diabetes were randomised to receive either insulin degludec or insulin glargine U100 (100 units/ml) once daily (between dinner and bedtime) in an event-driven, double-blind, treat-to-target cardiovascular outcomes trial. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE; cardiovascular death, non-fatal myocardial infarction or non-fatal stroke). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In the present analysis, the associations of severe hypoglycaemia with both MACE and all-cause mortality was evaluated in the pooled trial population using time-to-event analyses, with severe hypoglycaemia as a time-dependent variable and randomised treatment as a fixed factor. An investigation with interaction terms indicated that the effect of severe hypoglycaemia on the risk of MACE and all-cause mortality were the same for both treatment arms, and so the temporal association for severe hypoglycaemia with subsequent MACE and all-cause mortality is reported for the pooled population. RESULTS: There was a non-significant difference in the risk of MACE for individuals who had vs those who had not experienced severe hypoglycaemia during the trial (HR 1.38, 95% CI 0.96, 1.96; p = 0.080) and therefore there was no temporal relationship between severe hypoglycaemia and MACE. There was a significantly higher risk of all-cause mortality for patients who had vs those who had not experienced severe hypoglycaemia during the trial (HR 2.51, 95% CI 1.79, 3.50; p < 0.001). There was a higher risk of all-cause mortality 15, 30, 60, 90, 180 and 365 days after experiencing severe hypoglycaemia compared with not experiencing severe hypoglycaemia in the same time interval. The association between severe hypoglycaemia and all-cause mortality was maintained after adjustment for the following baseline characteristics: age, sex, HbA1c, BMI, diabetes duration, insulin regimen, hepatic impairment, renal status and cardiovascular risk group. CONCLUSIONS/INTERPRETATION: The results from these analyses demonstrate an association between severe hypoglycaemia and all-cause mortality. Furthermore, they indicate that patients who experienced severe hypoglycaemia were particularly at greater risk of death in the short term after the hypoglycaemic episode. These findings indicate that severe hypoglycaemia is associated with higher subsequent mortality; however, they cannot answer the question as to whether severe hypoglycaemia serves as a risk marker for adverse outcomes or whether there is a direct causal effect. TRIAL REGISTRATION: ClinicalTrials.gov NCT01959529.
引用
- Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2017. PMID: 28913543. doi:10.1007/s00125-017-4422-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。